AIM: To identify plasma analytes using metabolomics that correlate with the diagnosis and severity of liver disease in patients with alcoholic hepatitis (AH). METHODS: We prospectively recruited patients with cirrhosis from AH (n = 23) and those with cirrhosis with acute decompensation (AD) from etiologies other than alcohol (n = 25). We used mass spectrometry to identify 29 metabolic compounds in plasma samples from fasted subjects. A receiver operating characteristics analysis was performed to assess the utility of biomarkers in distinguishing acute AH from alcoholic cirrhosis. Logistic regression analysis was performed to build a predictive model for AH based on clinical characteristics. A survival analysis was used to construct Kaplan Meier curves evaluating transplant-free survival. RESULTS: A comparison of model for end-stage liver disease (MELD)-adjusted metabolomics levels between cirrhosis patients who had AD or AH showed that patients with AH had significantly higher levels of betaine, and lower creatinine, phenylalanine, homocitrulline, citrulline, tyrosine, octenoyl-carnitine, and symmetric dimethylarginine. When considering combined levels, betaine and citrulline were highly accurate predictors for differentiation between AH and AD (area under receiver operating characteristics curve = 0.84). The plasma levels of carnitine [0.54 (0.18, 0.91); P = 0.005], homocitrulline [0.66 (0.34, 0.99); P < 0.001] and pentanoyl-carnitine [0.53 (0.16, 0.90); P = 0.007] correlated with MELD scores in patients diagnosed with AH. Increased levels of many biomarkers (carnitine P = 0.005, butyrobetaine P = 0.32, homocitrulline P = 0.002, leucine P = 0.027, valine P = 0.024, phenylalanine P = 0.037, tyrosine P = 0.012, acetyl-carnitine P = 0.006, propionyl-carnitine P = 0.03, butyryl-carnitine P = 0.03, trimethyl-lisine P = 0.034, pentanoyl-carnitine P = 0.03, hexanoyl-carnitine P = 0.026) were associated with increased mortality in patients with AH. CONCLUSION: Metabolomics plasma analyte levels might be used to diagnose of AH or help predict patient prognoses.
AIM: To identify plasma analytes using metabolomics that correlate with the diagnosis and severity of liver disease in patients with alcoholic hepatitis (AH). METHODS: We prospectively recruited patients with cirrhosis from AH (n = 23) and those with cirrhosis with acute decompensation (AD) from etiologies other than alcohol (n = 25). We used mass spectrometry to identify 29 metabolic compounds in plasma samples from fasted subjects. A receiver operating characteristics analysis was performed to assess the utility of biomarkers in distinguishing acute AH from alcoholic cirrhosis. Logistic regression analysis was performed to build a predictive model for AH based on clinical characteristics. A survival analysis was used to construct Kaplan Meier curves evaluating transplant-free survival. RESULTS: A comparison of model for end-stage liver disease (MELD)-adjusted metabolomics levels between cirrhosispatients who had AD or AH showed that patients with AH had significantly higher levels of betaine, and lower creatinine, phenylalanine, homocitrulline, citrulline, tyrosine, octenoyl-carnitine, and symmetric dimethylarginine. When considering combined levels, betaine and citrulline were highly accurate predictors for differentiation between AH and AD (area under receiver operating characteristics curve = 0.84). The plasma levels of carnitine [0.54 (0.18, 0.91); P = 0.005], homocitrulline [0.66 (0.34, 0.99); P < 0.001] and pentanoyl-carnitine [0.53 (0.16, 0.90); P = 0.007] correlated with MELD scores in patients diagnosed with AH. Increased levels of many biomarkers (carnitine P = 0.005, butyrobetaine P = 0.32, homocitrulline P = 0.002, leucine P = 0.027, valine P = 0.024, phenylalanine P = 0.037, tyrosine P = 0.012, acetyl-carnitine P = 0.006, propionyl-carnitine P = 0.03, butyryl-carnitine P = 0.03, trimethyl-lisine P = 0.034, pentanoyl-carnitine P = 0.03, hexanoyl-carnitine P = 0.026) were associated with increased mortality in patients with AH. CONCLUSION: Metabolomics plasma analyte levels might be used to diagnose of AH or help predict patient prognoses.
Entities:
Keywords:
Alcoholic hepatitis; Biomarkers; Cirrhosis; Liver biopsy; Liver disease; Metabolomics; Model for end-stage liver disease
Authors: Alina Elena Pârvu; Vasile Negrean; Luminiţa Pleşca-Manea; Angela Cosma; Anton Drăghici; Ana Uifălean; Remus Moldovan Journal: Rom J Gastroenterol Date: 2005-09
Authors: Paolo Angeli; Pere Gines; Florence Wong; Mauro Bernardi; Thomas D Boyer; Alexander Gerbes; Richard Moreau; Rajiv Jalan; Shiv K Sarin; Salvatore Piano; Kevin Moore; Samuel S Lee; Francois Durand; Francesco Salerno; Paolo Caraceni; W Ray Kim; Vicente Arroyo; Guadalupe Garcia-Tsao Journal: Gut Date: 2015-01-28 Impact factor: 23.059
Authors: Ibrahim A Hanouneh; Nizar N Zein; Frank Cikach; Luma Dababneh; David Grove; Naim Alkhouri; Rocio Lopez; Raed A Dweik Journal: Clin Gastroenterol Hepatol Date: 2013-09-10 Impact factor: 11.382
Authors: Zeneng Wang; Bruce S Levison; Jennie E Hazen; Lillian Donahue; Xin-Min Li; Stanley L Hazen Journal: Anal Biochem Date: 2014-04-01 Impact factor: 3.365
Authors: Naaventhan Palaniyappan; Venkataraman Subramanian; Vidyasagar Ramappa; Stephen D Ryder; Philip Kaye; Guruprasad P Aithal Journal: Int J Hepatol Date: 2012-09-04
Authors: Roland Amathieu; Mohamed N Triba; Pierre Nahon; Nadia Bouchemal; Walid Kamoun; Hakim Haouache; Jean-Claude Trinchet; Philippe Savarin; Laurence Le Moyec; Gilles Dhonneur Journal: PLoS One Date: 2014-02-19 Impact factor: 3.240
Authors: Robert N Helsley; Tatsunori Miyata; Anagha Kadam; Venkateshwari Varadharajan; Naseer Sangwan; Emily C Huang; Rakhee Banerjee; Amanda L Brown; Kevin K Fung; William J Massey; Chase Neumann; Danny Orabi; Lucas J Osborn; Rebecca C Schugar; Megan R McMullen; Annette Bellar; Kyle L Poulsen; Adam Kim; Vai Pathak; Marko Mrdjen; James T Anderson; Belinda Willard; Craig J McClain; Mack Mitchell; Arthur J McCullough; Svetlana Radaeva; Bruce Barton; Gyongyi Szabo; Srinivasan Dasarathy; Jose Carlos Garcia-Garcia; Daniel M Rotroff; Daniela S Allende; Zeneng Wang; Stanley L Hazen; Laura E Nagy; Jonathan Mark Brown Journal: Elife Date: 2022-01-27 Impact factor: 8.713